Posted by Michael Wonder on 23 May 2025
Relief Therapeutics receives FDA rare paediatric disease designation for RLF-TD011
22 May 2025 - Relief Therapeutics today announced that the US FDA has granted rare paediatric disease designation to RLF-TD011 for the treatment of epidermolysis bullosa, a rare genetic skin disorder characterised by fragile skin and chronic wounds.
The FDA had previously granted orphan drug designation to RLF-TD011 for the same indication.
